Biotechnology · global
Circio and Avenue Team Up to Improve Protein Secretion, Shifting a Gene Therapy Challenge Toward Expression Efficiency
Gene therapy must not only deliver genes into cells, but also enable cells to stably produce sufficient amounts of protein; the collaboration between Circio and Avenue targets precisely this often underestimated manufacturing and expression bottleneck.
As gene therapy moves from rare diseases toward a broader range of chronic and immune diseases, the real challenge often lies not only in “delivering” genes, but in whether, after delivery, cells can produce the proteins needed for treatment over the long term, stably and efficiently. The research collaboration announced on July 16 by Norwegian biotech company Circio Holding ASA and Avenue Biosciences puts the focus on this step, which appears less often in headlines but may affect efficacy and dose design.
According to the companies’ announcement, the collaboration will combine Circio’s circVec circular RNA expression technology with Avenue Biosciences’ machine learning-assisted signal peptide engineering platform. The goal is to improve secretion efficiency and long-term expression when secreted proteins are expressed through gene therapy. Potential applications include AAV vector delivery of secreted therapeutic proteins, and could even extend to antibody-like molecules.
Manufacturing protein inside the cell is only the first step. If the therapeutic strategy requires the protein to be secreted outside the cell and enter tissues or the circulatory system, the signal peptide at the front end of the protein acts like an address label, influencing whether it can correctly enter the secretory pathway. Avenue’s role is to carry out initial screening to identify signal peptides that may improve secretion of proteins expressed by circVec; Circio then expects to conduct in vitro and in vivo testing to assess whether these designs can translate into actual expression advantages.
Circio’s circVec technology, which the company has emphasized in recent years, is based on the idea of using circular RNA’s relative resistance to rapid cellular degradation to pursue more durable protein expression than traditional mRNA. If this design can be combined with an AAV delivery system, it could theoretically have the opportunity to reduce the need for repeat dosing and make gene therapy more suitable for diseases that require long-term protein supplementation. However, the current announcement remains at the research collaboration stage and has not yet provided specific drug candidates, disease indications, animal data, or a timeline for human trials.
Avenue Biosciences’ machine learning platform also reflects a more granular use of AI in the biotech industry: not broadly “using AI to find drugs,” but applying algorithms to a specific problem in protein sequence design. Differences in signal peptides may affect secretion efficiency, protein folding, and cellular burden, but sequences screened by AI still need to be validated in cell models and animal studies; increased secretion itself also does not equal improved efficacy, and protein quality, immune responses, and safety must still be confirmed.
The industry significance of this collaboration is that competition in gene therapy is gradually shifting from single vector platforms toward the ability to combine vectors, expression systems, and protein engineering. For AAV therapies, limited vector capacity, immunogenicity, and manufacturing costs are all long-term constraints; if expression efficiency improves, it may help reduce the required dose, but this remains a hypothesis that requires experimental data to support it, not a clinical conclusion that can be applied immediately.
The key question ahead is not the collaboration itself, but whether the two companies can disclose comparable validation results: which types of proteins benefit, whether the magnitude of secretion improvement is stable, how long in vivo expression can be maintained, and whether it comes with safety trade-offs. For readers, this is not news that a new therapy is about to reach the market, but a signal that the basic engineering of gene therapy is advancing toward greater precision.